Lyell Immunopharma, Inc. — Form 4
Filed November 5, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 78/100
What the filing says
10% owner ARCH Venture Fund XIII, L.P. (LYEL) bought 2.3M shares (~$25.0M) on the open market (38% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
Tradability signal
NO TRADE
No trade: positive news with only -0.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.80% over 4 hrs, n=371). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $15.34 | +10 min · unknown $15.24 ▼ 0.62% | +30 min · unknown $15.90 ▲ 3.68% | +1 hr · unknown $15.23 ▼ 0.68% | +4 hrs · unknown $15.07 ▼ 1.73% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.